rs6421571

This is a intergenic variant variant.

GWAS Catalog Trait Associations (3)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

primary biliary cirrhosis

Allele C
OR 1.39
p 2.0e-13
N 13,239
Meta-analysisLarge GWAS
European

biliary liver cirrhosis

Allele C
OR 1.37
p 3.0e-12
N 7,003
Large GWAS
European

atopic eczema

Allele T
OR 0.07
p 3.0e-9
N 837,496
Large GWAS
multi-ancestry

Research that mentions this SNP (2)

Novel Rheumatoid Arthritis Susceptibility Locus at 22q12 Identified in an Extended UK Genome‐Wide Association Study
AssociationN=8,305Gisela Orozco et al.(2014)· Arthritis &amp; Rheumatology

This extended UK genome-wide association study identified a novel rheumatoid arthritis susceptibility locus at 22q12 (rs1043099, P = 6.9 × 10⁻⁹, OR = 0.84) in 3,034 cases and 5,271 controls, and confirmed 16 previously known RA loci, strengthening evidence for genetic contributors to RA in the UK population.

Traits studied:Rheumatoid arthritis
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis
AssociationN=4,215Bridget Charbonneau et al.(2013)· Cancer Immunology, Immunotherapy

A clinic-based case-control study of 2,694 NHL cases and 1,521 controls found that five of ten CXCR5 tag SNPs were associated with non-Hodgkin lymphoma risk, with rs1790192 showing the strongest association (increased risk of follicular lymphoma). Paradoxically, rs1790192 was also associated with superior event-free survival in follicular lymphoma patients, suggesting different roles of CXCR5 in lymphoma initiation versus progression.

Traits studied:Chronic lymphocytic leukemiaDiffuse large B-cell lymphomaFollicular lymphomaMantle cell lymphomaMarginal zone lymphomaNon-Hodgkin lymphomaPeripheral T-cell lymphomaSmall lymphocytic lymphoma

This variant is in our database but has no known associations or PRS memberships yet.

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…